



Indian Pharmaceutical Alliance

A-205 Sangam, 14B S V Road, Santacruz West, Mumbai 400 054, India
Tel: +91-22-2610 9281 □ Fax: +91-22-2610 9282 □ Cell: +91-98201 84258
Email: sudarshan.jain@ipa-india.org

24 March 2022

By Email/Courier

Dr Sumit Garg
Deputy Secretary
Department of Pharmaceuticals
Shastri Bhawan, Dr Rajendra Prasad Bhawan
New Delhi 110001

Dear Dr Garg,

Information regarding Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Indian Pharmaceutical Alliance (IPA) appreciate for reaching out to seek information on compliance of UCPMP by letter dated 17 March 2022. We welcome the Department of Pharmaceuticals initiative to take feedback on a regular basis for effective implementation of the UCPMP Code.

Indian Pharmaceutical Alliance (IPA) supports that the companies should refrain from using unfair practices for influencing medical practitioners and should adhere to Uniform Code for Pharmaceutical Marketing Practices (UCPMP). We have communicated zero tolerance policy for UCPMP Code violation. As requested, we submit the following:

- a) **Details of all the Complaints received and the disposal including the manner in which they were disposed since inception of the code, in a tabular manner.**

None

- b) **Whether, currently, the ECPMP is in place and share the details of the ECPMP members.**

IPA is a CEO driven forum. The complaint is received by the complaint officer and presented to the IPA Executive Council. The Executive Council meeting is held once in a quarter. As per the process, complaint will be discussed in the Executive Council meeting and course of action will be taken thereof.

- c) **Whether there is any portal or online mechanism to receive the complaints by ECPMP and dispose the same with a communication to the Complainant.**

Yes, the UCPMP guidelines are uploaded onto our website (<https://www.ipa-india.org/?s=ucpmp>) with the name of the complaint officer mentioned therein.

- d) **If so, pl share the link of the portal, that belongs to the Association.**

As in (c)

Indian Pharmaceutical Alliance

- e) **Whether, currently, the AEPMP is in place and share the details of the ECMPM members.**

IPA is a CEO driven forum. The complaint is received by the complaint officer and presented to the IPA Executive Council. The Executive Council meeting is held once in a quarter. As per the process, complaint will be discussed in the Executive Council meeting and course of action will be taken thereof.

We have been regularly submitting quarterly report to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority. The Reports are attached hereto.

We remain committed to the UCPMP and to providing quality medicines to the patients in India.

Yours sincerely,
For Indian Pharmaceutical Alliance



Archana Jatkar
Associate Secretary General

Proforma for furnishing quarterly return on complaints received and action thereafter by industries Association as per para (8) of UCPMP code

1	Name of Association	Indian Pharmaceutical Alliance
2	Date of uploading UCPMP alongwith detail procedure on website of association	20 August 2022
3	Whether the committees viz ECPMP & ACEPMP have been formed	Y/N
	i. if yes (mention date)	IPA Executive Committee is responsible
	ii. if not, reason thereof	
	iii. Likely Date of Formation	
4	i. No. of complaints received upto 31.12.2021	None
	ii. No. of complaints disposed off upto 31.12.2021	None
	iii. Details of complaints received & decision thereon by association	Not Applicable (NA)
5	i. No. of appeal received upto 31.12.2021	None
	ii. No. of appeal disposed off upto 31.12.2021	NA
	iii. Detail of appeal & decision thereon by association	NA
6	i. No. of complaint received during quarter ending December, 2021	None
	ii. No. of complaint disposed off during quarter — ending December 2021	NA
	iii. Details of the complaint & decision thereon on each complaint	NA
7	i. No. of appeal received during quarter ending December, 2021	None
	ii. No. of appeal disposed off during quarter ending December, 2021	NA
	iii. Details of appeal & decision thereon for each appeal	NA
8	Submission of quarterly report to NPPA	<ul style="list-style-type: none"> - We have been sharing quarterly reports from 2020 with the Department of Pharmaceutical - This is a high priority area for IPA.

Authorised Signatory:
 Name: Archana Jatkar
 Designation: Associate Secretary
 General

Place: Mumbai
 Date: 25.01.2022

Proforma for furnishing quarterly return on complaints received and action thereafter by industries Association as per para (8) of UCPMP code

1	Name of Association	Indian Pharmaceutical Alliance
2	Date of uploading UCPMP alongwith detail procedure on website of association	25 August 2020
3	Whether the committees viz ECPMP & ACEPMP have been formed	Y/N
	i. if yes (mention date)	IPA Executive Committee is responsible
	ii. if not, reason thereof	
	iii. Likely Date of Formation	
4	i. No. of complaints received upto 31.03.2021	None
	ii. No. of complaints disposed off upto 31.03.2021	None
	iii. Details of complaints received & decision thereon by association	Not Applicable (NA)
5	i. No. of appeal received upto 30.06.2021	None
	ii. No. of appeal disposed off upto 30.06.2021	NA
	iii. Detail of appeal & decision thereon by association	NA
6	i. No. of complaint received during quarter ending September, 2021	None
	ii. No. of complaint disposed off during quarter — ending June, 2021	NA
	iii. Details of the complaint & decision thereon on each complaint	NA
7	i. No. of appeal received during quarter ending September, 2021	None
	ii. No. of appeal disposed off during quarter ending September, 2021	NA
	iii. Details of appeal & decision thereon for each appeal	NA
8	Submission of quarterly report to NPPA	<ul style="list-style-type: none"> - We have been sharing quarterly reports from 2020 with the Department of Pharmaceutical - This is a high priority area for IPA.

Authorised Signatory:
 Name: Archana Jatkar
 Designation: Associate Secretary
 General

Place: Mumbai
 Date: 29.10.2021

Proforma for furnishing quarterly return on complaints received and action thereafter by industries Association as per para (8) of UCPMP code

1	Name of Association	Indian Pharmaceutical Alliance
2	Date of uploading UCPMP alongwith detail procedure on website of association	25 August 2020
3	Whether the committees viz ECPMP & ACEPMP have been formed	Y/N
	i. if yes (mention date)	IPA Executive Committee is responsible
	ii. if not, reason thereof	
	iii. Likely Date of Formation	
4	i. No. of complaints received upto 31.03.20 21	None
	ii. No. of complaints disposed off upto 31.03.2021	None
	iii. Details of complaints received & decision thereon by association	Not Applicable (NA)
5	i. No. of appeal received upto 31.03.2021	None
	ii. No. of appeal disposed off upto 31.03.2021	NA
	iii. Detail of appeal & decision thereon by association	NA
6	i. No. of complaint received duiring quarter ending June, 2021	None
	ii. No. of complaint disposed off during quarter — ending June, 2021	NA
	iii. Details of the complaint & decision thereon on each complaint	NA
7	i. No. of appeal received during quarter ending June, 2021	None
	ii. No. of appeal disposed off during quarter ending June, 2021	NA
	iii. Details of appeal & decision thereon for each appeal	NA
8	Submission of quarterly report to NPPA	<ul style="list-style-type: none"> - We have been sharing quarterly reports from 2020 with the Department of Pharmaceutical - This is a high priority area for IPA.

Authorised Signatory:
 Name: Archana Jatkar
 Designation: Associate Secretary
 General

Place: Mumbai
 Date: 26.07.2021

12.04.2021

By Email

To,
Mr Rajneesh Tingal
Joint Secretary
Department of Pharmaceuticals
Shastri Bhawan, Dr Rajendra Prasad Bhawan
New Delhi – 110001
India

Dear Mr Tingal,

Subject – Quarterly Report on Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Indian Pharmaceutical Alliance (IPA) appreciates the Department of Pharmaceuticals initiative to take a feedback on a regular basis for effective implementation of the UCPMP Code.

Indian Pharmaceutical Alliance (IPA) supports that the companies should refrain from using unfair practices for influencing medical practitioners and should adhere to Uniform Code for Pharmaceutical Marketing Practices (UCPMP).

The UCPMP has been uploaded onto our website (www.ipa-india.org). We have communicated zero tolerance policy for UCPMP Code violation. In the quarter from January 2021–March 2021, we have not received any complaints under the Code, hence no action initiated.

We remain committed to the UCPMP and to providing quality medicines to the patients in India.

Yours sincerely,
For Indian Pharmaceutical Alliance


Sudarshan Jain
Secretary General

08.01.2021

By Email

To,
Mr Navdeep Rinwa
Joint Secretary
Department of Pharmaceuticals
Room No 218, Shastri Bhawan
Dr Rajendra Prasad Bhawan
New Delhi – 110001
India

Dear Mr Rinwa,

Subject – Quarterly Report on Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Indian Pharmaceutical Alliance (IPA) appreciates the Department of Pharmaceuticals initiative to take a feedback on a regular basis for effective implementation of the UCPMP Code.

Indian Pharmaceutical Alliance (IPA) supports that the companies should refrain from using unfair practices for influencing medical practitioners and should adhere to Uniform Code for Pharmaceutical Marketing Practices (UCPMP).

The UCPMP has been uploaded onto our website (www.ipa-india.org). We have communicated zero tolerance policy for UCPMP Code violation. In the quarter from September 2020–December 2020, we have not received any complaints under the Code, hence no action initiated.

We remain committed to UCPMP and to providing quality medicines to the patient in India.

Yours sincerely,
For Indian Pharmaceutical Alliance


Sudarshan Jain
Secretary General



Indian Pharmaceutical Alliance

A-205 Sangam, 14B S V Road, Santacruz West, Mumbai 400 054, India
Tel: +91-22-2610 9281 □ Fax: +91-22-2610 9282 □ Cell: +91-98201 84258
Email: sudarshan.jain@ipa-india.org

03.09. 2020

To
Mr Navdeep Rinwa
Joint Secretary
Department of Pharmaceuticals
Room No 218, Shastri Bhawan
Dr Rajendra Prasad Bhawan
New Delhi – 110001
India

Dear Mr Rinwa,

Subject – Quarterly Report on Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Indian Pharmaceutical Alliance (IPA) would like to thank you for providing an opportunity to give our inputs on UCPMP. We appreciate the Department of Pharmaceuticals initiative to convene a meeting of the stakeholders on a regular basis for effective implementation of the Code.

Indian Pharmaceutical Alliance (IPA) supports that the companies should refrain from using unfair practices for influencing medical practitioners and should adhere to Uniform Code for Pharmaceutical Marketing Practices (UCPMP).

The UCPMP has been uploaded onto our website (www.ipa-india.org). We have communicated zero tolerance policy for UCPMP Code violation. In the quarter from January –March 2020, April – June 2020 and from June-August 2020, we have not received any complaints under the Code, hence no action initiated.

We remain committed to UCPMP and to providing quality medicines to the patient in India.

Yours sincerely,
For Indian Pharmaceutical Alliance


Sudarshan Jain
Secretary General